Minnesota House Bill HF2851

Minnesota 2025-2026 Regular Session

• Introduced: 3/26/25
• Refer: 3/26/25

Caption

Reverse auction procurement requirement for SEGIP pharmacy benefit contracts modified, use of spread pricing by pharmacy benefit managers prohibited, license application fees increased, fiduciary duties imposed, and money appropriated.

Impact

The implications of HF2851 extend to how prescription drugs are priced and how pharmacy benefit managers operate in Minnesota. By banning spread pricing, which allows PBMs to charge different prices for drugs than they pay pharmacies, the legislation is positioned to introduce greater price transparency and potentially decrease drug costs for consumers. Furthermore, by raising application fees, the bill ensures that only adequately funded PBMs can operate, thereby maintaining a higher standard of management in pharmacy benefits and reducing conflicts of interest.

Summary

House File 2851 (HF2851) aims to modify the procurement requirements for pharmacy benefit contracts under the State Employee Group Insurance Program (SEGIP). It notably prohibits the use of spread pricing by pharmacy benefit managers (PBMs), which has been a significant concern due to its potential to inflate medication costs for consumers and insurers. The bill also seeks to increase the licensing application fees for PBMs, imposes fiduciary duties, and allocates state funds for enforcement efforts related to these regulations.

Contention

There may be concerns surrounding how HF2851 could affect the complexity of pharmaceutical pricing and the relationships between PBMs, pharmacies, and patients. Critics may argue that increasing operating costs through higher fees could lead to increased drug prices or reduced competition in the pharmaceutical marketplace. Moreover, while proponents argue for the ethical responsibilities placed on PBMs, the enforcement of fiduciary duties could present challenges in compliance and oversight, potentially leading to additional regulatory burdens.